scholarly journals Dataset for the reporting of nephrectomy specimens for wilms’ tumour treated with preoperative chemotherapy: recommendations from the international society of paediatric oncology renal tumour study group

2021 ◽  
Author(s):  
Gordan M Vujanić ◽  
Ellen D’Hooghe ◽  
Christian Vokuhl ◽  
Paola Collini
Keyword(s):  
Preoperative Chemotherapy ◽  
International Society ◽  
Paediatric Oncology ◽  
Renal Tumour ◽  
Study Group ◽  
Wilms Tumour

Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms’ tumour: Results of a randomised trial (UKW3) by the UK Children’s Cancer Study Group

2006 ◽  
Vol 42 (15) ◽  
pp. 2554-2562 ◽  
Author(s):  
Christopher Mitchell ◽  
Kathy Pritchard-Jones ◽  
Rosemary Shannon ◽  
Carolyn Hutton ◽  
Suzanne Stevens ◽  
...  
Keyword(s):  
Preoperative Chemotherapy ◽  
Randomised Trial ◽  
Study Group ◽  
Wilms Tumour ◽  
Cancer Study ◽  
Cancer Study Group ◽  
The Uk

Clear Cell Sarcomas of the Kidney registered on International Society of Pediatric Oncology (SIOP) 93-01 and SIOP 2001 protocols: A report of the SIOP Renal Tumour Study Group

2013 ◽  
Vol 49 (16) ◽  
pp. 3497-3506 ◽  
Author(s):  
R. Furtwängler ◽  
S.L. Gooskens ◽  
H. van Tinteren ◽  
J. de Kraker ◽  
G. Schleiermacher ◽  
...  
Keyword(s):  
International Society ◽  
Pediatric Oncology ◽  
Clear Cell ◽  
Renal Tumour ◽  
Study Group

scholarly journals Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study

2016 ◽  
Vol 34 (26) ◽  
pp. 3195-3203 ◽  
Author(s):  
Tasnim Chagtai ◽  
Christina Zill ◽  
Linda Dainese ◽  
Jenny Wegert ◽  
Suvi Savola ◽  
...  
Keyword(s):  
Preoperative Chemotherapy ◽  
International Society ◽  
Copy Number ◽  
Prognostic Biomarker ◽  
Wilms Tumor ◽  
Multivariable Analysis ◽  
Paediatric Oncology ◽  
Hazard Ratio ◽  
Localized Disease ◽  
1Q Gain

Purpose Wilms tumor (WT) is the most common pediatric renal tumor. Treatment planning under International Society of Paediatric Oncology (SIOP) protocols is based on staging and histologic assessment of response to preoperative chemotherapy. Despite high overall survival (OS), many relapses occur in patients without specific risk factors, and many successfully treated patients are exposed to treatments with significant risks of late effects. To investigate whether molecular biomarkers could improve risk stratification, we assessed 1q status and other potential copy number biomarkers in a large WT series. Materials and Methods WT nephrectomy samples from 586 SIOP WT 2001 patients were analyzed using a multiplex ligation-dependent probe amplification (MLPA) assay that measured the copy number of 1q and other regions of interest. Results One hundred sixty-seven (28%) of 586 WTs had 1q gain. Five-year event-free survival (EFS) was 75.0% in patients with 1q gain (95% CI, 68.5% to 82.0%) and 88.2% in patients without gain (95% CI, 85.0% to 91.4%). OS was 88.4% with gain (95% CI, 83.5% to 93.6%) and 94.4% without gain (95% CI, 92.1% to 96.7%). In univariable analysis, 1q gain was associated with poorer EFS (P < .001; hazard ratio, 2.33) and OS (P = .01; hazard ratio, 2.16). The association of 1q gain with poorer EFS retained significance in multivariable analysis adjusted for 1p and 16q loss, sex, stage, age, and histologic risk group. Gain of 1q remained associated with poorer EFS in tumor subsets limited to either intermediate-risk localized disease or nonanaplastic localized disease. Other notable aberrations associated with poorer EFS included MYCN gain and TP53 loss. Conclusion Gain of 1q is a potentially valuable prognostic biomarker in WT, in addition to histologic response to preoperative chemotherapy and tumor stage.

Sign in / Sign up

Export Citation Format

Share Document